Sun Pharma Advanced Research Company Limited

Quick facts

Phase 3 pipeline

• Reference0912 · Oncology
  Reference0912 is a drug that targets the PD-1 receptor.
• SDN-037 · Diabetes
  SDN-037 is a small molecule that targets the SGLT2 receptor.
• SPARC0912 · Oncology
  SPARC0912 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to modulate gene expression and induce anti-tumor effects.
• SPARC0913
  SPARC0913 is a small molecule that targets the molecular target.
• SPARC0921 · Diabetes
  SPARC0921 is a small molecule that targets the SGLT2 receptor.
• SPARC1104 modified dose regimen I · Oncology
  SPARC1104 modified dose regimen I is a drug that targets the PD-1/PD-L1 pathway.
• SPARC1104 modified dose regimen II
  SPARC1104 is a modified dose regimen of an undisclosed drug, but it is likely a small molecule targeting a specific molecular pathway.
• SPARC1104 modified dose regimen III
  SPARC1104 is a modified dose regimen of an undisclosed compound, details of which are not publicly available.

Phase 2 pipeline

• SPARC1102 I
• SPARC1102 II
• SPARC1102 III
• SPARC1103 high dose
• SPARC1103 low dose
• SPARC1203
• SPARC1310 I
• SPARC1310 II
• SPARC1310 III

Phase 1 pipeline

• Hydrocodon bitartrate-acetaminophen arm 1
• Ref-08-038
• Reference001 - Hydrocodone
• Reference001 type I
• Reference001 type II
• Reference147609
• Reference147709
• Reference1613
• SCO-120
• SPARC-08-038
• SPARC001 type I
• SPARC001 type II
• SPARC001A
• SPARC001B
• SPARC1023 I
• SPARC1023 II
• SPARC1028
• SPARC1316 Dose 1
• SPARC147609
• SPARC147709
• SPARC1613

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sun Pharma Advanced Research Company Limited portfolio CI brief
• Sun Pharma Advanced Research Company Limited pipeline updates RSS